Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura

American Journal of Hematology

Volumn 83, Issue 10, 2008, Pages 815-817

  Dong, Lingli ^a,c   Chandrasekaran, Visalam ^b   Zhou, Wenhua ^a   Tsai, Han Mou ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ENZYME ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; METALLOPROTEINASE INHIBITOR; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SINGLE DRUG DOSE; SOMATIC HYPERMUTATION; TH1 CELL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE;

ADAM PROTEINS; ADOLESCENT; ADRENAL CORTEX HORMONES; AUTOANTIBODIES; ENZYME INHIBITORS; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN G; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS;

EID: 53549100752     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21217     Document Type: Article

References (18)

1. Tsai HM. Thrombotic thrombocytopenic purpura: A thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007;21:609-632.
2. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001;47:387-392.
3. Zhou W, Dong L, Ginsburg D, et al. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: A novel therapeutic strategy? J Biol Chem 2005;280:39934-39941.
4. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000;65:251-255.
5. Peled JU, Kuang FL, Iglesias-Ussel MD, et al. The biochemistry of somatic hypermutation. Ann Rev Immunol 2008;26:481-511.
6. Luken BM, Kaijen PH, Turenhout EA, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006;4:2355-2364.
7. Lu H, Wang M, Gunsolley JC, et al. Serum immunoglobulin G subclass concentrations in periodontally healthy and diseased individuals. Infect Immun 1994;62:1677-1682.
8. Mayumi M, Kuritani T, Cooper MD. T-cell regulation of IgG subclass expression by mitogen-induced plasma cells: Soluble factors versus the T cells. J Clin Immunol 1984;4:287-294.
9. Snapper CM, Waegell W, Beernink H, Dasch JR. Transforming growth factor-β 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J Immunol 1993;151:4625-4636.
10. Estes DM, Closser NM, Allen GK. IFN-γ stimulates IgG2 production from bovine B cells costimulated with anti-mu and mitogen. Cell Immunol 1994;154:287-295.
11. Kawano Y, Noma T, Yata J. Regulation of human IgG subclass production by cytokines. IFN-γ and IL-6 act antagonistically in the induction of human IgGI but additively in the induction of IgG2. J Immunol 1994;153:4948-4958.
12. Ishihara Y, Zhang JB, Quinn SM, et al. Regulation of immunoglobulin G2 production by prostaglandin E(2) and platelet-activating factor. Infect Immun 2000;68:1563-1568.
13. Kikuchi T, Hahn CL, Tanaka S, et al. Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells. Infect Immun 2004;72:5089-5096.
14. Zan H, Cerutti A, Dramitinos P, et al. Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: Definition of the requirements and modalities of hypermutation. J Immunol 1999;162:3437-3447.
15. Nagumo H, Agematsu K, Kobayashi N, et al. The different process of class switching and somatic hypermutation: A novel analysis by CD27(-) naive B cells. Blood 2002;99:567-575.
16. Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and regulation of class switch recombination. Ann Rev Immunol 2008;26:261-292.
17. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
18. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244.